

12/07/01  
J1133 U.S. PTO

PATENT  
ATTORNEY DOCKET NO.: 053529-5005-US

Jc835 U.S. PTO  
10/005907  
12/07/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner of Patents  
**BOX PATENT APPLICATION**  
Washington, D.C. 20231

**TRANSMITTAL FOR A NEWLY EXECUTED ORIGINAL APPLICATION  
UNDER 37 C.F.R. §1.53(b)**

This is a request for filing a patent application under 37 C.F.R. §1.53(b) for:

Inventors: Karl **NOCKA**, Gregory **PIROZZI** and Richard **EINSTEIN**

For: **NOVEL GENES ASSOCIATED WITH ALLERGIC HYPERSENSITIVITY  
AND MASS CELL ACTIVATION**

1. This is a new ☒ **Utility** patent application.
2. The papers enclosed to obtain a filing date are as follows:

66	Pages of Specification including
8	Pages of Claims
1	Page of Abstract
25	Pages of Sequence Listing
29	Sheets of drawings containing 29 Figures
<input type="checkbox"/> The enclosed drawings are photographs, and there is also attached a PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)	

3. Combined Declaration and Power of Attorney

☐ Enclosed and is executed by all inventors  
☒ Not Enclosed.  
This application is being filed under the provisions of 37 C.F.R. §1.53(f).  
Applicant(s) await notification from the Patent and Trademark Office of  
the time set for filing the Declaration and paying the filing fees.

## 4. Language



English



Non-English

This application is being filed in accordance with 37 C.F.R. §1.52(d) and §608.01 of the MPEP. Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the verified English translation and the processing fee.

## 5. Assignment



An assignment will be filed at a later date.

## 6. Priority - foreign applications under 35 U.S.C. §119(a)-(d) or §365(b) or PCT international applications under 35 U.S.C. §365(a) designating at least one country other than the U.S.

☐ Priority of the following foreign application is claimed:

Country	Application No.	Filed

Certified copy: ☐ is attached. ☐ will follow.

## 7. Priority based on provisional application(s) - 35 U.S.C. §119(e)

☒ Priority of the following provisional application(s) is claimed:

Application No.	Filed
60/251,835	December 8, 2000
60/275,479	March 14, 2001
60/279,115	March 28, 2001
60/280,143	April 2, 2001

## 8. Small entity status



Applicant(s) hereby assert(s) small entity status under 37 C.F.R. § 1.27.

## 9. Fee Calculation (37 C.F.R. §1.16)

	Number Filed	Number Extra	at Rate of	Basic Fee Utility \$740.00 Design \$330.00
			BASIC FEE	
Total Claims (37 C.F.R. §1.16(c))	- 20 =		18.00	
Independent Claims (37 C.F.R. §1.16(b))	- 3 =		84.00	
Multiple dependent claim(s), if any (37 C.F.R. §1.16(d))			280.00	
			SUB-TOTAL =	
			Reduction by 1/2 for filing by a small entity	
			TOTAL FILING FEE =	

## 10. Fee Payment

☒ Not Enclosed. **NO FEE IS BEING PAID BY CHECK OR DEPOSIT ACCOUNT AT THIS TIME.**

This application is being filed under the provisions of 37 C.F.R. §1.53(f). Applicant(s) await notification from the Patent and Trademark Office of the time set for filing the Declaration and paying the filing fees.

☐ Enclosed.

A check in the amount of \$\_\_\_\_\_ representing the basic filing fee of \$740.00 and an assignment recording fee of \$40.00 is enclosed

11. ☒ **Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

12. Additional papers enclosed:

- ☐ Preliminary Amendment
- ☐ Information Disclosure Statement
- ☐ Form PTO-1449, \_\_\_\_\_ document included
- ☐ Declaration of Biological Deposit
- ☒ Submission of "Sequence Listing", computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.

**Please accord this application an application number and filing date.**

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**

*Michael S. Tuscan*  
*Michael S. Tuscan*

*Reg. No. 43,210*

*for* F. Pierre VanderVegt, Ph.D.  
Reg. No. P-49,088

Dated: December 7, 2001

**Customer No. 09629**

**MORGAN, LEWIS & BOCKIUS LLP**

1800 M Street, NW

Washington, D.C. 20036

(202) 467-7000

FOUOCT 2065000T

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
 )  
 **K. NOCKA *et al.*** )  
 )  
 Application No.: Unassigned ) Group Art Unit: Unassigned  
 )  
 Filed: December 7, 2001 ) Examiner: Unassigned  
 )  
 For: **NOVEL GENES ASSOCIATED WITH** )  
 **ALLERGIC HYPERSENSITIVITY AND** )  
 **MAST CELL ACTIVATION** )

**Box Sequence**  
Commissioner for Patents  
Washington, D.C. 20231


**STATEMENT ACCOMPANYING SEQUENCE LISTING**

Dear Sir:

The undersigned hereby states upon information and belief that the information recorded on the diskette submitted concurrently herewith is identical to the written Sequence Listing submitted herewith.

Respectfully submitted,  
**MORGAN, LEWIS & BOCKIUS LLP**

Dated: December 7, 2001

By:   
F. Pierre VanderVegt

**Customer No. 009629**  
**MORGAN, LEWIS & BOCKIUS LLP**  
1800 M Street, NW  
Washington, D.C. 20036  
Tel: 202-467-7000  
Fax: 202-467-7258